‘New Frontiers’ series continues Dec. 11 with stem cell presentation – News at Louisiana Tech
News at Louisiana Tech |
‘New Frontiers’ series continues Dec. 11 with stem cell presentation
News at Louisiana Tech Gimble earned his bachelor’s in biology from Dartmouth College and his master’s, Ph.D., and M.D. from Yale University. He has published more than 250 peer-reviewed manuscripts on the isolation, characterization, and clinical application of adult stem … |
Rare Disease Report |
George Yohrling of the HDSA Explains AMT-130 Gene Therapy
Rare Disease Report Yohrling: The AMT-130 is a gene therapy, and it’s a Huntingtin-lowering approach that would be mediated through viral delivery of adeno-associated virus, or AAV. In the case of uniQure, they use AAV-5, which will deliver a micro-RNA, and this micro-RNA … |
|
FDA issues warning on DIY gene–therapy kits
BioNews ‘[The] FDA is aware that gene therapy products intended for self-administration and “do it yourself” kits to produce gene therapies for self-administration are being made available to the public,’ the agency said in a statement last week. ‘The sale of … |
|
Human stem cells help paraplegic rats walk again
BioNews ‘In the past, scientists have managed to rehabilitate and injured spinal cord using stem cells. But this is the first time that stem cells restored feeling in limbs and complex motor ability, including fast walking, in a significant way, within only a … |
Curetoday.com |
Examining Immunotherapy’s Role in Colorectal Cancer
Curetoday.com Is there thought of bringing immunotherapy into patients with microsatellite-stable CRC? There are trials that are looking at how we can combine checkpoint inhibitors, specifically PD-1/PD-L1 agents to perhaps sensitize them to an immuno-oncology drug. |
OncLive |
Alternative Treatment Options Emerging for Relapsed Pediatric Patients With ALL
OncLive In an interview with OncLive, Rheingold, medical director of the Oncology Outpatient Clinic, physician with the Cancer Center at Children’s Hospital of Philadelphia, discusses the impact of CAR T-cell therapy on patients with ALL and options for … |